931 related articles for article (PubMed ID: 23764078)
1. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
4. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
5. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
6. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
7. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB
J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
[TBL] [Abstract][Full Text] [Related]
8. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A
Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
[TBL] [Abstract][Full Text] [Related]
9. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
10. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
11. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
14. Progression and treatment of incident lower urinary tract symptoms (LUTS) among men in the California Men's Health Study.
Wallner LP; Slezak JM; Loo RK; Quinn VP; Van Den Eeden SK; Jacobsen SJ
BJU Int; 2015 Jan; 115(1):127-33. PubMed ID: 24840926
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
16. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
17. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
[TBL] [Abstract][Full Text] [Related]
20. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
